Health Benefits of Probiotics | OraMune

The term Probiotic literally means "for life" The World Health organization (WHO) defines a probiotic as live organisms which when taken in adequate amounts confer health benefits on the host. At the time of consumption the organisms should be viable and capable of surviving stomach acidity, gastric and duodenal proteolytic enzymes and adhere to the endothelial colon mucosal cells. There are literally hundreds of different genera and considerably more species of probiotic bacteria of which the Lactobacilli and Bifidobacteria make up the majority of gut microflora.

The health associated benefits of probiotics in food has been known for ages and include:

  • Enhanced intestinal immunity. Some 70 % of the immune system cells reside within the colon in a layer of lymphoid tissue called the lamina propia. The friendly bacteria stimulate these cells to promote both local and systemic protection against pathogens.
  • Protection against Helicobacter pylori bacteria known to cause ulcers and colon cancer particularly in children.
  • Positive effect on diarrhea, inflammatory bowel disease and irritable bowel syndrome.
  • Reduction of fever, coughing and runny noses in infants.
  • T cell (a population of lymphocytes) response to certain viral respiratory infections.
  • T cell production of TNF alpha upon exposure to certain viruses.
  • Enhanced phagocytosis by monocytes and neutrophils.
  • Stimulation of innate immune response and increased resistance to pathogens.
  • Reduced risks of eczema in infants, allergies and arthritis.
  • Cholesterol reduction.
  • Anti aging.

The positive actions of probiotics are tied to specific strains and specific doses. Thus the primary goal with any probiotic product is to deliver the right bacteria in ideal numbers to the right place in the body. To promote the growth and activity of friendly bacteria a synbiotic combination of probiotics and inulin a prebiotic (see review prebiotics) are offered in IMUNOBIOTICS. Prebiotics prepare the environment for probiotics to flourish and work at their best.


  1. Manners DJ, Mason AJ, Patterson JC. The structure of a beta-(1-3)-glucan from yeast cell walls. Biochem. J. 135: 19-30, 1973.
  2. Williams DL, Sherwood ER, Browder JW, etal. Pre clinical safety evaluation of soluble glucan. Int. J. Immunopharmacol. 10: 405-411, 1988.
  3. DI Luzio NR. Pharmacology of the reticuloendothelial system: accent on glucan. In The Reticuloendothelial System in Health and Disease. Reichard S, Escobar M, and Friedman H, eds. New York, Plenum Press, pp 412-421, 1976.
  4. Wooles WR, DI Luzio NR, The phagocytic and proliferative response of reticuloendothelial system following glucan administration. J. Reticuloendothelial Sec. 1: 160, 1964.
  5. Czop LK, Kay j. Isolation and characterization of beta glucan receptors on human mononuclear phagocytes. J. Exp. Med. 173: 1511-1520, 1991.
  6. Taylor PR, Brown GD, Reid DM, Willment JA, etal. The beta-glucan receptor, Dectin-1 is predominantly expressed on the surface of cells of the monocyte/ macrophage and neutrophil lineages. J. Immunol. 169: 3876-3882, 2002.
  7. Brown GD, Taylor PR, Reid DM, Willment JA, etal. Dectin-1 is a major beta-glucan receptor on macrophages. J. Exp. Med. 196: 407-412, 2002.
  8. Herr J, Marshall AS, Caron E, Edwards AD, etal. Derctin-1 utilizes novel mechanisms for yeast phagocytosis in macrophages. Blood Aug 10 (pub ahead of print).
  9. Suzuki I, Tanaka H, Kinoshita A, Oikawa S, etal. Effect of orally administered beta-glucan on macrophage function in mice. Int. J. Immunopharmacol. 12:675-678, 1990.
  10. Kokoshis PL, Williams DL, Cook JA, Di Luzio NR. Increased resistance to Staphylococcus aureus infection and enhaucement in serum lysozyme activity by glucan. Science 24: 1340-1342, 1978.
  11. Di Luzio NR, Williams DL, McNamee RB, Malshet VG. Comparative evaluation of the tumor inhibitory and antibacterial activity of solubilized and particulate glucan. Recent results cancer res. 75: 165-72, 1980.
  12. Reynolds JA, Kastello MD, Harrington DG, Crabbs CL. Glucan-induced enhaucement of host resistance to selected infectious diseases. Infect. Immun. 30: 51-57, 1980.
  13. Williams DL, Sherwood ER, Brewder IW, Mcnamee RB, etal. Effect of glucan on neutrophil dynamics and immune function in Escherichia coli peritonitis. J. Surg. Res. 44: 54-61, 1988.
  14. Williams DL, Di Luzio NR. Glucan-Induced modification of murine Viral hepatitis. Science 208: 67-69, 1980.
  15. Bistoni F, Vecchiarelli A, Cenci E, puccetti P, etal. Evidence for macrophage-mediated protection against lethal Candida albicns infection. Infect. Immun. 51: 668-674, 1986.
  16. Williams DL, Cook JA, Hoffman EO, etal. Protective effect of glucan in experimentally induced candidiasis. J. Reticulocndothelial Soc. 23: 479-490, 1978.
  17. Di Luzio NR, McNamee R, Browder WI, Williams D. Glucan: Inhibition of tumor growth and enhancement of survival in four syngeneic murine tumor models. Cancel Treat. Rep. 62: 1857-1866, 1978.
  18. Di Luzio NR, Williams DL, McNamee RB, etal. Comparative tumor inhibitory and anti-bacterial activity of soluble and particulate glucan. Int. J. Cancer. 24: 773-779, 1979.
  19. Di Luzio NR, McNamee R, Jones E, etal. The employment of glucan and glucan activated macrophages in the enhancement of host resistance to malignancies in experimental animals. In M. D. Fink ed. The Macrophage in Neoplasia, pp. 181-198, Academic Press, New York 1976.
  20. Mansel PWA, etal. Macrophage-mediated destruction of human malignant cells in vivo. J. Natl. Cancer Inst. 54: 571-580, 1975.
  21. Stewart CC, etal. Preliminary observations on the effect of glucan in combination with radiation and chemotherapy in four murine tumors. Cancer Treat. Rep. 62: 1867-1872, 1978.
  22. Di Luzio NR, Cook JA, Cohen C, etal. Enhancement of the inhibitory effect of cyclophosphamide on experimental acute myclogenous leukemia by glucan immunopotentiation and the response of serum lysozyme. In control of Neoplasia by Modulation of the Immune System. Ed. M. Chigiros. New York, Raven press 1978.
  23. Sveinbjornsson B. Inhibition of extablishemtn and growth of mouse liver metastases after treatment with interferon gamma and bet-1,3-glucan. Hepatology 27: 1241-1248, 1998.
  24. Gyorgy A. Czop JK. Stimulation of human monocyte beta glucan receptors by glucan particies induces production of UNF alpha and IL-1 beta. J. Immunopharmac. 14:1363-1372, 1992.
  25. Patcheu MI., Mac Vittie TJ. Stimulation of hemopoiesis and euhanced survival following glucan treatment in sub lethally and lethally irradiated mice. Int J. Immunopharmacol. 7:923-923, 1985
  26. Patchen MI., D' Alesandro MM, Brook I, etal. Glucan: mechanisms involved in its "radio protective" effect. J. Leukoe Biol. 24:95-105, 1987.
  27. Patchen MI., MacVittie TJ, Brook I. Glucan-induced hemopoietic and immune stimulation: therapeutic effects in sub lethally and lethally irradiated mice. Methods Find. Exp. Chin, Pharmacol. 8:151-155, 1986.
  28. Walk M, Danon D. Promotion of wound healing by yeast glucan evaluated on single animals. Med Biol. 63:73-80, 1985.